Neuropace Stock Analysis

Neuropace Stock Analysis Notes

About 94.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.75. Neuropace had not issued any dividends in recent years. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people. To find out more about Neuropace contact Michael Favet at 650 237 2700 or learn more at https://www.neuropace.com.

Neuropace Investment Alerts

Neuropace Largest EPS Surprises

View All Earnings Estimates

Neuropace Environmental, Social, and Governance (ESG) Scores

Neuropace Stock Institutional Investors

Note, although Neuropace's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Neuropace Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 501.28 M.

Neuropace Profitablity

The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1.

Management Efficiency

Neuropace has return on total asset (ROA) of (0.1119) % which means that it has lost $0.1119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6927) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2026, Return On Tangible Assets is expected to decline to -0.27. In addition to that, Return On Capital Employed is expected to decline to -0.33. At present, Neuropace's Debt To Assets are projected to slightly decrease based on the last few years of reporting.

Technical Drivers

As of the 16th of February 2026, Neuropace secures the Mean Deviation of 2.39, downside deviation of 2.46, and Risk Adjusted Performance of 0.0625. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 15.05 per share. Given that Neuropace has jensen alpha of 0.1074, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.

Neuropace Price Movement Analysis

Neuropace Insider Trading Activities

Neuropace Outstanding Bonds

Neuropace Predictive Daily Indicators

Neuropace Corporate Filings

Neuropace Forecast Models

Neuropace's time-series forecasting models are one of many Neuropace's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neuropace's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Neuropace Bond Ratings

Neuropace financial ratings play a critical role in determining how much Neuropace have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Neuropace's borrowing costs.

Neuropace Debt to Cash Allocation

Neuropace currently holds 73.34 M in liabilities with Debt to Equity (D/E) ratio of 1.08, which is about average as compared to similar companies. Neuropace has a current ratio of 9.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neuropace's use of debt, we should always consider it together with its cash and equity.

Neuropace Total Assets Over Time

Neuropace Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Neuropace uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Neuropace Debt Ratio

117.0

It looks as if most of the Neuropace's assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Neuropace's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Neuropace, which in turn will lower the firm's financial flexibility.

Neuropace Corporate Bonds Issued

Neuropace Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Neuropace prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neuropace shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Neuropace. By using and applying Neuropace Stock analysis, traders can create a robust methodology for identifying Neuropace entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neuropace analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neuropace analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Neuropace stock analysis indicators help investors evaluate how Neuropace stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neuropace shares will generate the highest return on investment. By understating and applying Neuropace stock analysis, traders can identify Neuropace position entry and exit signals to maximize returns.

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.